TNFRSF17 and plasma cell myeloma: Antibodies like #55, which was together with the CD38 binding antibody #5 the most frequent antibody (≥10%) after two rounds of panning, may target low expressed antigens on myeloma cells, which can be – comparable to BCMA – suitable targets for highly potent immunotherapeutic approaches (4, 5).